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Oral keratinocytes synthesize CTACK: A new insight into the pathophysiology of the oral mucosa Abstract
The skin-associated chemokine CTACK plays a key role in many inflammatory conditions and could be instrumental in the pathophysiology of tissue-specific immunological diseases such as oral lichen planus (OLP). In this study, we investigated, by RT-PCR, ELISA, chemotaxis assays, and fluorescence-activated cell sorting (FACS), the production of CTACK in oral keratinocytes, its expression in tissues from normal and OLP patients, and its role in T-cell recruitment.
CTACK was produced by the oral epithelium, and it affects chemotaxis of memory CLA+ cells to the oral epithelium. CTACK mRNA was expressed constitutively in primary oral epithelium and was increased during pro-inflammatory IFN-γ treatment. We found a constitutive production of CTACK at a protein level in oral primary cells that increased after IFN-γ treatment. Moreover, we confirmed that CTACK attracts memory T cells and those T cells that express CLA above the level of basal migration.
| BACKGROUND
Lichen planus (LP) is a chronic T cell-mediated mucocutaneous inflammatory disease that targets the stratified epithelia. There is increasing evidence that epithelial-derived cytokines, immune receptors and costimulatory molecules promote and sustain the disease. [1] [2] [3] [4] Oral lichen planus (OLP) is known to be associated with production of IFN-γ by infiltrating T lymphocytes.
Cutaneous T-cell attractant chemokine CTACK, also known as CCL27, is known for its properties to attract memory T cells. CTACK is highly expressed in the skin, both normal and inflamed, specifically by keratinocytes in the epidermis. [5] The oral cavity has many immunological features in common with the skin; however, the role of CTACK in the oral cavity immunity has yet to be investigated. Further, anti-CCL27 was found to be more potent than tacrolimus at reducing inflammation in skin patients, highlighting a potential therapeutic role. [6] [7] [8] [9] [10] [11] 
| QUESTIONS ADDRESSED
The aim of this study was to investigate the production of CTACK in oral keratinocytes, its expression in tissues from normal and OLP patients, and its role as a chemotactic molecule mediating T-cell recruitment.
| EXPERIMENTAL DESIGN
Three primary normal oral keratinocyte strains (NHOK1, NHOK2, NHOK3), the UP cell line [12] and the H357 [13] cell line were used in this study.
The cells were tested with TNF-α, IL-1β and IFN-γ treatment or no treatment (for 3, 6 or 24 hours). RT-PCR was used to assess the expression of CTACK mRNA in epithelial cell lines. The supernatants were also tested for the presence of the CTACK protein using ELISA.
Peripheral blood mononuclear cells were prepared from fresh blood obtained from healthy patients. Cell supernatants derived from the cytokine treatment assays were incubated with no antibody, monoclonal anti-human CTACK antibody or mouse anti-human IgG 2a isotype control, for 30 minutes before placing in transwell.
Antibodies utilised to label the migrated PBL were monoclonal mouse anti-human CD45RO-R-phycoerythrin, monoclonal rat antihuman CLA-FITC and monoclonal mouse anti-human CD3 Cy-chrome.
The migrated cell populations were then analysed using a florescence activated cell sorter (FACS) machine.
Materials and methods are described under Data S1.
| RESULTS
CTACK mRNA was expressed in primary unstimulated oral keratinocytes, and levels were increased when treated with IFN-γ ( Figure 1A ,B).
The ELISA test showed an increased production of CTACK in NHOK2, and a similar trend in NHOK1 and NHOK3 ( Figure 1C ).
However, the biological triplicate showed a statistically significant difference (P = .023638313) between the IFN-γ-treated and non-treated cell lines. The average concentration produced in the IFN-γ-treated cells was 557.74 and 302.85 pg/mL in the unstimulated cells.
CTACK was released from the oral carcinoma cell line, H357, in similar concentrations to the oral primary cell line ( Figure 1D ), suggesting that H357 is an adequate study model for CTACK over time.
CTACK was produced by untreated H357 cells, but the concentration produced decreases over time in culture. TNF-α-and IL-1β-treated cells released lower concentrations of CTACK at 3 hours compared to the untreated cells, but the amount increased over each time point and was significantly increased to the untreated cells after 6 and 24 hours.
IFN-γ treatment was also able to significantly increase the concentration of CTACK in this cell type after 24 hours ( Figure 1D ).
In the UP cell line, CTACK was detected in untreated cells at all time points. IFN-γ treatment slightly increased CTACK production at 3 and 24 hours compared to control cells, but not to a significant level. Similarly, TNF-α and IL-1β treatments increased the production of CTACK at 24 hours ( Figure 1D ).
The cell populations were analysed after migration with the peripheral blood lymphocyte population and gated upon the CTACK mRNA was expressed in the oral inflammatory disorder OLP and in NOM, however, to low levels and to differing degrees in different samples ( Figure S2 ).
| CONCLUSIONS
CTACK is constitutively produced by oral keratinocytes, and increases during pro-inflammatory, IFN-γ, cytokine treatment.
Further, it actively affects chemotaxis of memory CLA+ cells to the oral epithelium. This is the first report of a tissue-specific chemokine being produced by cells in the oral cavity. It suggests that CTACK may play a role in early recruitment of T cells that could be instrumental in the pathophysiology of tissue-specific immunological diseases such as OLP.
Surprisingly, in OLP and NOM tissue, low-level CTACK mRNA was expressed in most of the samples tested; however, CTACK may still play a role in progressing OLP lesions and not the chronic lesions tested in this study.
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All authors have read and approved the final version of the manuscript. patients, 5 (22.7%) harboured a BRAF mutation, which was much higher than the rate of 5% reported in the literature. One patient, who was tested negative on the primary melanoma, had a NRAS mutation in a cutaneous metastasis. Our data provide a rationale for prospective and repeated mutations testing in female lower genital tract melanomas.
| BACKGROUND
In the past few years, several studies attempting to identify mutations in melanomas have opened the door for targeted therapies with the discovery of BRAF, NRAS and KIT mutations. When focusing on melanomas of the female lower genital tract, differences with cutaneous ones were observed concerning prognosis, treatment and also probably the pattern of mutations. Indeed, some recent studies suggest that KIT mutations are more common in vulvar melanomas and that BRAF mutations are less frequent in vulvar and vaginal melanomas than in cutaneous ones. [1] [2] [3] [4] [5] [6] 
| QUESTION ADDRESSED
Because available data on BRAF, NRAS and KIT mutations are scarce in patients with vulvar and vaginal melanomas and are associated with important therapeutic issues, we investigated their prevalence in a cohort of patients with female lower genital tract melanomas seen in our skin cancer unit.
